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comments on our study. Individuals with He-
reditary Diffuse Gastric Cancer (HDGC) syn-drome face the difficult decision of when to proceed with
a gastrectomy that could eliminate the risk for gastric
cancer but at a significant cost in quality of life. This
decision must be confronted as early as 20–30 years of
age. Many patients will choose to defer surgery, but there
have been limited data on their outcomes. In our expe-
rience with this unique group of patients, cancer-related
outcomes in patients who pursued endoscopic
surveillance were similar to in those who pursued
immediate gastrectomy.
The question of targeted vs random biopsies in endo-
scopic surveillance is a good one. Our protocol included
biopsies of any suspicious lesions as well as random
samples. The overall rate of detection of foci of signet ring
cell cancer (SRCC) was lower than the highest rate re-
ported in the literature1 butwas not dissimilar to others.2,3
These variations may reflect differences in patient pop-
ulations, endoscopic and imaging devices, and subjective
assessments of endoscopic abnormalities. It is noteworthy
that scars from prior endoscopic biopsies are not easily
distinguished from pale spots that may harbor SRCC. A
broader question that remains unanswered is the clinical
significance of recognizing microscopic foci of SRCC dur-
ing endoscopy. Specifically, is the identification of such
lesions associated with a higher subsequent risk of inva-
sive gastric cancer, and will promptly proceeding to gas-
trectomy influence the natural history of the disease? It is
well recognized that nearly all gastrectomy specimens
from HDGC patients, even those in their early 20s, will
harbor multiple microscopic foci of SRCC. However, the
mean age of gastric cancer diagnosis is much older, at 47
years, and recent reports have revised the lifetime risk of
invasive gastric cancer downward from 70% to 37%–
42%.4,5 Not everymicroscopic focus of SRCCwill progress,
and the development of a specific endoscopic or histologic
marker that could inform the true risk of progression
would be of great value.Our results do not alter the existing recommendation
that gastrectomy is the definitive approach for cancer
risk reduction in HDGC. The current findings suggest that
endoscopic surveillance may also have a role, but more
precise risk stratification among CDH1 mutation carriers
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https://doi.org/10.1016/j.cgh.2020.01.016The Challenges of Managing Inflammatory
Bowel Diseases in Older PatientsDear Editor:
With great interest we have read the review by Singh
et al1 discussing the challenges and solutions in the man-
agement of obese, older, and obstetric patients with in-
flammatory bowel disease (IBD). We would like to react on
the second population described, namely the older patient.
Indeed little evidence is available on (treatment of) older
patients with IBD. Despite this lack of evidence, the au-
thors propose a so-called evidence-derived algorithm on
the treatment of older patients with IBD (Figure 2). We
agree with the authors that characterizing the older patient
not merely based on chronologic age, but based on patient
characteristics reflecting a biologic age, such as frailty,
could be an essential aspect of future therapy guidelines in
older patients with IBD.
June 2020 Letters to the Editor 1649However, we do have some difficulty with the
distinction made between fit and frail. The proposed al-
gorithm suggests that frailty is an entity that is either
absent or fully present. Frailty, however, is a complex
term with little consensus on its definition.2 When frailty
is suspected, it is best measured by a comprehensive
geriatric assessment, which assesses all geriatric do-
mains. These domains comprise (1) somatic status (ie,
the presence of multiple comorbidities, polypharmacy,
and malnutrition), (2) mental status (ie, the presence of
cognitive impairment or depression), (3) functional sta-
tus (ie, dependency in [instrumental] activities of daily
living and physical status), and (4) social status (ie, the
presence of social support). The previously mentioned
domains are then integrated into an assessment of the
overall level of frailty. Such an algorithm as proposed by
Singh et al1 should not be focusing on frailty as a binary
entity, but rather display a gradual scale from absence of
geriatric impairments to a state of impairment in all
geriatric domains. With an increase in the number of
impaired domains, physicians could be advised to pay
more attention to clinical rather than endoscopic
remission and focus more on quality of life, such as
preserving self-dependence or keeping the ability to
maintain social contacts. Factors influencing quality of
life differ greatly between patients and these factors
could partly define therapy choices and treatment goals.
However, very little evidence on geriatric impairments in
older patients with IBD is available and more research is
needed on the prevalence of geriatric impairments and
the impact on adverse health outcomes or quality of life
in this population.3
Furthermore, we note the authors’ choices on
preferred IBD medication in both the “non-frail” and
“frail” patient groups. In the proposed treatment algo-
rithm, immunomodulators have no place in treatment of
both groups, even though methotrexate is safe in older
patients with Crohn’s disease because of its low risk on
lymphoproliferative disorders or nonmelanoma skin
cancer compared with other immunomodulators.4 The
use of methotrexate should therefore not be ruled out in
older patients with IBD, especially in patients without
impairments in their geriatric domains.
Furthermore, although the authors state in their
manuscript that there are limited data on safety of
non–tumor necrosis factor-a targeted biologic agents in
older patients, they suggest starting vedolizumab or
ustekinumab therapy in corticosteroid-dependent frail
older patients. However, both therapies require a certain
fitness of patients because these therapies have to be
administered subcutaneously at home or require
frequent hospital visits because of intravenous adminis-
tration. Additionally, no data are presented about the
effect of comorbid diseases on treatment outcomes in
patients on vedolizumab and ustekinumab therapy. Thus,
at least frequent monitoring of these patients with
“multiple suboptimally controlled comorbidities” should
be advised.In conclusion, the IBD research field needs more ev-
idence on older patients with IBD. We definitely support
the use of a more biologic age–based treatment algo-
rithm in the older patient with IBD; however, the term
“frailty” is vague and should not be used as a binary
entity. The proposed treatment options are, in our
opinion, not evidence-derived and this treatment algo-
rithm should be seen as a call for more research, rather
than evidence-derived.
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We welcome their recommendation for moreevidence to help inform the management of older pa-
tients with inflammatory bowel disease in daily clinical
practice. We completely agree that frailty is not a binary
state, and exists as a spectrum, with impairment poten-
tially impacting multiple domains to varying extent (so-
matic, mental, functional, and social status). Our intent
was to highlight the distinction between chronological
age and fitness, in determining optimal management
strategies. We agree that a comprehensive and struc-
tured assessment of frailty be routinely considered in the
management of older patients. With regard to our pro-
posed pharmacologic management of older patients with
inflammatory bowel disease, we acknowledge that this
represents our opinion, based on our interpretation and
extrapolation on the comparative efficacy and safety of
pharmacotherapies.2 Although studies have not directly
compared the biologic monotherapy versus metho-
trexate monotherapy, indirect comparisons suggest that
biologic therapy may be more effective than
